View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsVoyager Acquisition 배당 및 자사주 매입배당 기준 점검 0/6Voyager Acquisition 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • May 17Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 VACH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: VACH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Voyager Acquisition 배당 수익률 vs 시장VACH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (VACH)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Capital Markets)2.0%분석가 예측 (VACH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VACH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VACH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VACH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: VACH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 00:42종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Voyager Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • May 17Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.